Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report

Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report

BackgroundHalf of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approv...

Full description

Bibliographic Details
Main Authors: Jingyi Wang, Xiaoqing Li, Juan Zhou, Dan Qiu, Mengyao Zhang, Lan Sun, Shengwen Calvin Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
anti-angiogenesis therapy
front-line treatment
elderly patients
case report
Anlotinib hydrochloride
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1043244/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1043244/full

Similar Items